Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925315 | 1.00 | HCRTR1 (0.43) | HCRTR1HCRTR2GPR119DPP4MEN1 | |
| SCHEMBL2925316 | 1.00 | HCRTR1 (0.43) | HCRTR1HCRTR2GPR119DPP4MEN1 | |
| SCHEMBL7079164 | 0.79 | PRMT5 (0.48) | HCRTR1HCRTR2DPP4 | |
| SCHEMBL7079166 | 0.79 | PRMT5 (0.48) | HCRTR1HCRTR2DPP4 | |
| SCHEMBL2932749 | 0.77 | HCRTR2 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL2930100 | 0.76 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL2930099 | 0.76 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL2931958 | 0.75 | HCRTR1 (0.36) | HCRTR1HCRTR2GPR119KMT2A | |
| SCHEMBL2931957 | 0.75 | HCRTR1 (0.36) | HCRTR1HCRTR2GPR119KMT2A | |
| SCHEMBL1340254 | 0.75 | HCRTR1 (0.36) | HCRTR1HCRTR2GPR119KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079690-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008038251-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-03 | — | — | WO | disclosed |